BiotechTube
Home/Pipeline/KHR‑002

KHR‑002

Cystic Fibrosis

PreclinicalActive

Key Facts

Indication
Cystic Fibrosis
Phase
Preclinical
Status
Active
Company
KAHR Medical

About KAHR Medical

Israeli biotech delivering CRISPR‑derived gene‑editing and mRNA therapeutics for rare diseases and oncology.

View full company profile

Therapeutic Areas

Genetic DisordersOncology

Other Cystic Fibrosis Drugs

DrugCompanyPhase
CB-280Calithera BiosciencesPreclinical/Phase 1
EnsifentrineVerona PharmaPhase 2
ALTA Drug SeriesAlteron TherapeuticsPreclinical
ColiFin®SpexisMarketed (EU)
Cystic fibrosis (CRISPR)GeneToBeDiscovery
Cystic fibrosis (undisclosed)GeneToBeEarly Discovery
SM001 (alidornase/Tigerase)SarcoMed USAResearch
Targeted Lung DeliveryNanitePre-clinical
CFTR 100+ PanelAgena BioscienceCommercial
RIG-301 CFTRRIGImmunePre-clinical
CBN-101Carbon BiosciencesPreclinical
RESP® Biosensor Evaluation (with Rutgers Health)Strados LabsResearch Study